Avanir Pharmaceuticals, Inc. announced the electronic publication of the results of the pivotal Phase III STAR trial of its investigational drug AVP-923 (dextromethorphan/quinidine) in the Annals of Neurology.
The publication entitled "Dextromethorphan Plus Ultra-Low-Dose Quinidine Reduces Pseudobulbar Affect" evaluated two low dose formulations compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).
PBA is a neurologic condition characterized by involuntary, unpredictable and disruptive outbursts of laughing or crying in patients with certain underlying neurologic diseases or injuries....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2882